SynthesisBMC psychiatry2015
Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis.
Synthesis in BMC psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 4 syntheses or guidelines pooled it, 88 citations in OpenAlex.
- Safety of aripiprazole for tics in children and adolescents: A systematic review and meta-analysis.Medicine · 2019Pooled it
- Safety and efficacy of combined use of propofol and etomidate for sedation during gastroscopy: Systematic review and meta-analysis.Medicine · 2019Pooled it
- Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis.International journal of impotence research · 2017Pooled it
- Bevacizumab and wound-healing complications: a systematic review and meta-analysis of randomized controlled trials.Oncotarget · 2016Pooled it
- Pain in Tourette Syndrome: A Comprehensive Review.Journal of child and adolescent psychopharmacology · 2025Review
- Tic Cough in an Adolescent with Organic Brain Pathology-A Case Report and Literature Review.Brain sciences · 2024Article
- Medical outcomes of children with neurodevelopmental disorders after SARS-CoV-2 vaccination: A six-month follow-up study.Vaccine · 2023Article
- The Sapap3Translational psychiatry · 2023Article
- European clinical guidelines for Tourette syndrome and other tic disorders-version 2.0. Part III: pharmacological treatment.European child & adolescent psychiatry · 2022Review
- Tourette Syndrome Treatment Updates: a Review and Discussion of the Current and Upcoming Literature.Current neurology and neuroscience reports · 2022Review
- Dopamine receptors in emesis: Molecular mechanisms and potential therapeutic function.Pharmacological research · 2020Review
- Current Status, Diagnosis, and Treatment Recommendation for Tic Disorders in China.Frontiers in psychiatry · 2020Review
- The evidence-based choice for antipsychotics in children and adolescents should be guaranteed.European journal of clinical pharmacology · 2019Review
- Safety and efficacy of aripiprazole for the treatment of pediatric Tourette syndrome and other chronic tic disorders.Pediatric health, medicine and therapeutics · 2016Review
- Clinical Profile of Tic Disorders in Children and Adolescents from a Tertiary Care Center in India.Indian journal of psychological medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTic disorders (TDs) are common neuropsychiatric disorders in children. Typical antipsychotics, such as haloperidol and pimozide have been prescribed to control tic symptoms as first-line agents. However, adverse effects have led to the use of newer atypical antipsychotics. Aripiprazole is one of alternatives. The aim of this study was to evaluate the efficacy and safety of aripiprazole for children with TDs.
methodsRandomized controlled trials (RCTs), quasi-RCTs and control studies evaluating aripiprazole for children with tic disorders were identified from PubMed, Embase, Cochrane library, Cochrane Central, four Chinese database and relevant reference lists. Quality assessment referred to the Cochrane Handbook for Systematic Reviews of Interventions.
resultsTwelve studies involving 935 participants were included. The general quality of included studies was poor. Only one study used placebo as a control and others used positive drug controls. Participants were aged between 4 and 18 years. The period of treatment ranged from 8 to 12 weeks. Seven studies (N = 600 patients) used the YGTSS scale as the outcome measurement, and there was no significant difference in reduction of the total YGTSS score between the aripiprazole and positive control groups (MD = -0.48, 95 % CI [-6.22, 5.26], P = 0.87, I(2) = 87 %). Meta-analysis of four of the studies (N = 285 patients) that compared aripiprazole with haloperidol showed that there was no significant difference in reduction of the total YGTSS score (MD = 2.50, 95 % CI [-6.93, 11.92], P = 0.60, I(2) = 88 %). Meta-analysis of two studies (N = 255 patients) that compared aripiprazole with tiapride showed that there was no significant difference in reduction of the total YGTSS score (MD = -3.15, 95 % CI [-11.38, 5.09], P = 0.45, I(2) = 86 %). Adverse events (AEs) were reported in 11 studies. Drowsiness (5.1 %-58.1 %), increased appetite (3.2 %-25.8 %), nausea (2 %-18.8 %) and headache (2 %-16.1 %) were common AEs.
conclusionIn conclusion, aripiprazole appears to be a promising therapy for children with TDs. Further well-conducted RCTs are required to confirm this issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.